AZ 960 is a novel ATP competitive JAK2 inhibitor with IC50 and Ki of <3 nM and 0.45 nM, 3-fold selectivity of AZ960 for JAK2 over JAK3.

AZ0108 is an orally bioavailable phthalazinone PARP inhibitor with enzyme IC50 of <30/<30/83 nM for PARP1/2/6 respectively.

AZ084 (AZ-084) is a potent, selective, allosteric, orally available CCR8 antagonist with Ki of 0.9 nM.

AZ-1 is a small molecule inducer of ABCA1 and apoE that act through indirect activation of the LXR pathway, shows purinergic receptor P2X7 antagonist activity.

AZ10397767 is a potent, selective CXCR2 inhibitor that inhibits CXCL8 binding to CXCR2 with pIC50 of 9.0.

AZ10606120 is a potent, specific P2X7 receptor antagonist with Kd of 1.4 and 19 nM at human and rat P2X7 receptors respectively.

AZ12204657 (AZ-12204657) small-molecule GPR44 antagonist, displaces the binding of [3H]PGD2 from membranes of HEK293 cells transfected with human recombinant GPR44 with IC50 of 2.5 nM.

AZ12441970 is a selective TLR7 agonist with pEC50 of 6.8 and 6.6 for human and rat TLR7, shows inactivity against TLR8.

AZ12601011 (AZ-12601011) is a potent, selective inhibitor of ALK4, ALK7 and TGFBR1 (Kd=2.9 nM), inhibits TGFβ-induced reporter activity with IC50 of 18 nM.

AZ12799734 (AZ-12799734) is a pan BMP/TGFβ inhibitor that potently inhibits ligand activated SMAD3/4 transcription with IC50 of 47 nM, inhibits receptor-mediated phosphorylation of SMAD1 by ALK1, BMPR1A and BMPR1B and phosphorylation of SMAD2 by ALK4, TGF

AZ-1355 is an effctive lipid-lowering compound that inhibits platelet aggregation in vivo and elevates the prostaglandin I2/thromboxane A2 ratio in vitro..

AZ13705339 is a potent, selective PAK1 inhibitor with IC50 of 0.33 nM, displays 14-, 470-, 4100- and 2600-fold selectivity over Src, FGFR1, KDR and PAK4.

AZ13711265 is a potent, selective, in vivo active PAK1 inhibitor with IC50 of 0.58 nM, displays 880-, 2100- and 90-fold selectivity over Src, FGFR1, KDR and PAK4.

AZ1729 is a novel direct, positive allosteric modulator of fatty acid receptor FFA2 (pEC50=6.9), selectively activates Gi signaling but lacks the capacity to activate FFA2 Gq/G11-mediated signaling pathways.

AZ-2 is a small molecule inducer of ABCA1 and apoE that act through indirect activation of the LXR pathway, shows purinergic receptor P2X7 antagonist activity.

AZ-23 is a potent, selective, orally bioavailable Trk kinase inhibitor with IC50 of 2 and 8 nM for TrkA and TrkB, respectively.

AZ-4217 is a potent and selective, orally active, brain-permeable BACE1 inhibitor with IC50 of 160 pM in human SH-SY5Y cells.

AZ6197 (AZ-6197) is a potent, selective, reversible inhibitor of ERK1/2 with IC50 of <0.3 nM (ERK2), inhibits pERK/pRSK with IC50 of 12/62 nM in A375 cells, respectively.

AZ82 is a selective HSET/KIFC1 inhibitor, with a Ki of 43 nM and an IC50 of 300 nM for KIFC1.

AZ-8838 (AZ8838) is a potent, and selective PAR2 antagonist with Kd of 125 nM.

AZ8838 racemate(AZ-8838 racemate) is the racemate form of AZ8838, which is a potent, and selective PAR2 antagonist with Kd of 125 nM..

AZ9482, a potent and selective PARP inhibitor featuring an amide linkage to a 2-piperazinyl-3-cyano-pyridine.